Vitro Biopharma Inc (DELISTED) (VTRO:DL)
Vitro Biopharma Cash from Financing (TTM): 1.619M for July 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
| Date | Value |
|---|---|
| July 31, 2023 | 1.619M |
| April 30, 2023 | 0.8242M |
| Date | Value |
|---|---|
| January 31, 2023 | -0.3378M |
| October 31, 2022 | -1.109M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-1.109M
Minimum
Oct 2022
1.619M
Maximum
Jul 2023
0.2492M
Average
0.2432M
Median
Cash from Financing (TTM) Benchmarks
| Perspective Therapeutics Inc | 167.19M |
| Electromed Inc | 0.149M |
| Xtant Medical Holdings Inc | 20.30M |
| Asensus Surgical Inc | 10.92M |
| Senseonics Holdings Inc | 31.21M |